Alaunos TherapeuticsTCRT
Recorded

Alaunos Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration23 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Morning, everyone. Thank you for coming today. At UBS, we are very excited to host this conference here in London as our inaugural Global Biopharma Conference. We are excited that in this second day, we have even more investors, even more turnout, corporates coming in. Looking forward to another great day of meeting folks and having discussions and presentations like this one. I am excited to introduce Velaris Therapeutics, and specifically Michael Henderson as Chief Executive Officer, and Carl Dambkowski as Head of Research and Development.

Michael HendersonPresident

Great. Thanks very much for the opportunity. For those of you that are not in the room, it is a hard transition because there was some very nice upbeat techno music, like the UBS house music, I guess, right before this. Now you get to hear us, so we will try to keep the beats going. No, thank you for the opportunity to be here and for attending. Really excited to tell you about Velaris Therapeutics today. We will be making a number of forward-looking statements throughout this, as you should expect. Velaris is developing really a strategy and pipeline for some of the largest cardiopulmonary conditions out there. Specifically, PAH, pulmonary hypertension, group two heart disease, right, HFpEF, heart failure with preserved ejection fraction due to pulmonary hypertension, and group three lung diseases.

Michael HendersonPresident

Think pulmonary hypertension, ILD, IPF, and a number of potential blockbuster expansions, which we will get into. This is really born out of the insight that there is an incredible mechanism and activin biology that sotatercept, now Winrevair, which Merck acquired Acceleron for, has proven remarkably effective in PAH. Recent data in heart failure is also quite strong. However, right, similar to many first-in-class drugs, hindsight is 20/20, we think that there are ways that we can improve upon that first-in-class precedent in terms of clinical strategy, dose optimization, and also just bringing combinations via a wholly owned pipeline to these diseases in a way that nobody else can because they do not have all these mechanisms.

Michael HendersonPresident

Not only are we advancing our lead, VLR199, which binds similarly to how sotatercept binds within PAH and these indications, we are also bringing a PDGFB antibody into the clinic next year alongside our lead VLR199, and that could be a mono with combination potential. There are a number of next-generation approaches that spare BMP-9/10 that others have pursued that we have unique insights that we are advancing forward as well, and that is VLR247 and VLR258. Kind of a number of layers of value creation in some of the largest, least competitive markets that are out there in quite severe conditions that we are very excited to share more about. A bit more about Winrevair. It has been a somewhat under-the-radar launch, just, right, Merck has a lot going on, which is fair.

Michael HendersonPresident

But doing $2 billion in its second year in PAH alone, on track to be about $8 billion in PAH alone. I think that this sets us up to be potentially one of the largest new classes out there. Again, with high unmet need and very little competition. Nobody's really tracking behind Winrevair with positive data yet. To put this into context, you can see in the dark blue on the left, this $8 billion in peak is in the smallest potential indication we think that we could bring to bear. Heart failure, specifically HFpEF, Merck just put out a very nice hazard ratio of 0.18 in heart failure, which has not really been seen, right? Heart failure right now is mostly failure, so really striking results. This was only at the low dose, though. The high dose underperformed, which again speaks to the need for dose optimization.

Michael HendersonPresident

We're excited to follow them in heart failure and do some more dose optimization. On the right, you can see four different lung indications where we believe we have a potential to be first in class by being first movers for reasons that we can get into, dynamics that work in our favor. A number of PAH drugs have gone into these respiratory conditions and done quite well, right? United Therapeutics with Tyvaso, right, kind of a number of blockbuster expansions there. Recently, Roivant with a drug that had been shelved for PAH going into PH-ILD with really remarkable phase II data, which was rewarded by the market. So, a nice precedented path that we also would plan to pursue. I'll hand it off to Carl now to talk a bit more about the biology and our drugs in particular.

Carl DambkowskiHead of Research and Development

Yeah. Thanks, Michael. One of the reasons we really believe there's this ability to expand beyond just PAH and HFpEF is that there's shared pathophysiology across these groups of pulmonary hypertension, group one being PAH, group two being cardiac-related ones, specifically HFpEF, and group three being lung-related diseases. That shared pathophysiology is really on the remodeling that happens at the pulmonary arterioles. What SOTA has done really well is figure out the balance between that remodeling too, between the pro-proliferative and the anti-proliferative ligands. In terms of the design of VLR199, which is the SOTA-like pipeline product we're developing too, we really tried to replicate the pharmacology of SOTA.

Carl DambkowskiHead of Research and Development

The reason for that is it captures a lot of ligands, not just a single target here, and the balance between capturing all those ligands we think is really important and is the reason for the efficacy that's being seen there. As Michael said, that efficacy is really best in class for pulmonary arterial hypertension, right? Looking at hazard ratios of 0.2 or less for clinical worsening across multiple indications now too. We've tried to, you can see on the right-hand side of the slides for those following along, right, you can see that that balance is something we've been able to achieve in terms of similarity between Winrevair, SOTA, and our lead VLR199.

Carl DambkowskiHead of Research and Development

As Michael said, there's a lot of areas where we think that they haven't completely optimized in terms of the path forward, which we'll talk about moving forward, and there's this ability to go beyond just PAH in terms of HFpEF. We're seeing really strong phase II data from Winrevair, ILD, where there is a really strong emerging case series. People are using this off-label and seeing very similar results to, if not even slightly improved to PAH alone. Then finally, multiple expansions beyond that, COPD, PPF, and other indications as well. We think that there's not only a PAH case here to be made, but a wide expansion opportunity that we can build on as well. For PAH specifically and how we plan to move there, we'll start off with a phase I study, specifically here in post-menopausal women.

Carl DambkowskiHead of Research and Development

The reason for that is one of the things that we can see in the phase I study is dose-dependent, predictable changes in FSH. That's on target for activin inhibition there, and really, that'll help us set up for phase I proof of concept data in first half of 2028. We'll be able to see these biomarker changes. Post-menopausal women will help us enrich for high baseline FSH, so we can see similar changes to what Winrevair saw. Really designing a phase I related to that. Then moving forward, we'll want to dose optimize here. I think one of the places that is underappreciated in terms of Winrevair is what is the right dose and our ability to improve on that. It's a Q3W dosing schedule where they only tested two doses in their phase II study.

Carl DambkowskiHead of Research and Development

I think there's room there to get better in terms of not only moving potentially from Q3W to Q4 week dosing, but also finding what is the truly optimized dose there and testing more than just those two regimens before moving to registrational approaches in PAH and potentially other indications. As mentioned, the phase I study for SOTA showed really nice dose-dependent changes across a variety of biomarkers. On the left-hand side here, we're showing that FSH change, but it doesn't just stop there. FSH is one of those. Bone biomarkers was another, and hemoglobin changes is a third that we can really look for there. That will allow us to really understand the pharmacology between our drug in the clinic as well as SOTA and pick the right doses to move forward in phase II planning.

Carl DambkowskiHead of Research and Development

The phase II, as mentioned a couple times, we really want to optimize the dose. As we look at the Winrevair data, obviously they've gone forward with 0.7, but I actually think it's a really mixed picture on whether that is the optimized dose or not. In their phase II study, they saw better PVR changes with 0.7, but no other endpoints, biomarkers, or six-minute walk tests really showed a differentiation in 0.7, and the 0.7 versus the 0.3 dose. The AE profile between 0.7 and 0.3 showed about 20%, two to three times worse hemoglobin, clinically significant heme changes with 0.7 than 0.3. So we think there's a lot of room there to understand more about what that benefit-risk trade-off is for 0.7 and 0.3 equivalent doses, but also potentially a dose in between those two. Then for phase III, we have a precedented regulatory pathway here.

Carl DambkowskiHead of Research and Development

We think that is really important, but I think there are areas to improve on here in terms of line of treatment. SOTA is doing quite well, as Michael had mentioned too, but getting into earlier lines of treatment is an area we can really potentially improve as well.

Michael HendersonPresident

Looking again beyond PAH, which, right, $8 billion indication, I think a ton of momentum from Merck there, ways that we can clearly improve. Just to put it into context, right, heart failure, approximately 10 times the number of potential patients, and again, a hazard ratio which was quite strong. Merck is now moving into phase III just with a single dose, right, no titration. We look to kind of learn from that and see what we can optimize. In these different lung diseases, not only do we think that this is an interesting idea, docs typically get there first.

Michael HendersonPresident

Docs are already using SOTA across a number of these different indications, and we will get into some of this data, but very convincing signal worthy of a proper experiment now in ILD, also in PH-COPD, very high unmet need, where other COPD drugs do not drive any benefit. IPF and PPF also really precedent pathways from other PH drugs. Excited to kind of try this. Just to put HFpEF a bit more in context, on the left, you can see the data that SOTA put up in PAH, hazard ratio of 0.16. Then in the middle, you can see that hazard ratio of 0.18 that we alluded to in heart failure, right? I think quite a convincing signal. It is a phase II study. This was only in the 0.3 dose, as Carl mentioned. 0.7, they did not show a strong benefit.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day